Literature DB >> 20634583

Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-β in plasma.

Esther S Oh1, Michelle M Mielke, Paul B Rosenberg, Alka Jain, Neal S Fedarko, Constantine G Lyketsos, Pankaj D Mehta.   

Abstract

Plasma amyloid-β (Aβ) level could be useful as a non-invasive biomarker in Alzheimer's disease research. We compared a multiplex electrochemiluminescence detection method with a well established ELISA method for plasma Aβ quantification. Compared to the ELISA method, the electrochemiluminescence detection method demonstrates a statistically significant, but modest correlation. The reasons for this may include the differences in the affinities of antibodies, and purity and source of Aβ peptides used as standards. However, the advantages of electrochemiluminescence detection technology include short processing time and small sample volume. This comparison demonstrates the need for a further study in optimizing this system.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20634583      PMCID: PMC3075593          DOI: 10.3233/JAD-2010-100456

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  19 in total

1.  Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA.

Authors:  Mohamed F Elshal; J Philip McCoy
Journal:  Methods       Date:  2006-04       Impact factor: 3.608

2.  Increased amyloid beta protein levels in children and adolescents with Down syndrome.

Authors:  Pankaj D Mehta; George Capone; Amy Jewell; Robert L Freedland
Journal:  J Neurol Sci       Date:  2007-02-02       Impact factor: 3.181

3.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

4.  Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

Authors:  Neill R Graff-Radford; Julia E Crook; John Lucas; Bradley F Boeve; David S Knopman; Robert J Ivnik; Glenn E Smith; Linda H Younkin; Ronald C Petersen; Steven G Younkin
Journal:  Arch Neurol       Date:  2007-03

5.  Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.

Authors:  M Bibl; B Mollenhauer; P Lewczuk; H Esselmann; S Wolf; C Trenkwalder; M Otto; G Stiens; E Rüther; J Kornhuber; J Wiltfang
Journal:  Mol Psychiatry       Date:  2007-03-06       Impact factor: 15.992

6.  Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease.

Authors:  R Mayeux; M X Tang; D M Jacobs; J Manly; K Bell; C Merchant; S A Small; Y Stern; H M Wisniewski; P D Mehta
Journal:  Ann Neurol       Date:  1999-09       Impact factor: 10.422

7.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

8.  Sensitive ELISA detection of amyloid-beta protofibrils in biological samples.

Authors:  Hillevi Englund; Dag Sehlin; Ann-Sofi Johansson; Lars N G Nilsson; Pär Gellerfors; Staffan Paulie; Lars Lannfelt; Frida Ekholm Pettersson
Journal:  J Neurochem       Date:  2007-07-10       Impact factor: 5.372

9.  Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay.

Authors:  N Ida; T Hartmann; J Pantel; J Schröder; R Zerfass; H Förstl; R Sandbrink; C L Masters; K Beyreuther
Journal:  J Biol Chem       Date:  1996-09-13       Impact factor: 5.157

10.  Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging.

Authors:  J Näslund; A Schierhorn; U Hellman; L Lannfelt; A D Roses; L O Tjernberg; J Silberring; S E Gandy; B Winblad; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

View more
  22 in total

1.  Plasma neopterin level as a marker of peripheral immune activation in amnestic mild cognitive impairment and Alzheimer's disease.

Authors:  Daniel C Parker; Michelle M Mielke; Qilu Yu; Paul B Rosenberg; Alka Jain; Constantine G Lyketsos; Neal S Fedarko; Esther S Oh
Journal:  Int J Geriatr Psychiatry       Date:  2012-04-27       Impact factor: 3.485

Review 2.  Exploring Biomarkers for Alzheimer's Disease.

Authors:  Neeti Sharma; Anshika Nikita Singh
Journal:  J Clin Diagn Res       Date:  2016-07-01

3.  Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues.

Authors:  Sid E O'Bryant; Guanghua Xiao; Fan Zhang; Melissa Edwards; Dwight C German; Xiangling Yin; Tori Como; Joan Reisch; Ryan M Huebinger; Neill Graff-Radford; Dennis Dickson; Robert Barber; James Hall; Padraig O'Suilleabhain; Paula Grammas
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

4.  Association of plasma β-amyloid 40 and 42 concentration with type 2 diabetes among Chinese adults.

Authors:  Xiaobo Peng; Zihui Xu; Xiaoxing Mo; Qianqian Guo; Jiawei Yin; Mengdai Xu; Zhao Peng; Taoping Sun; Li Zhou; Xiaolin Peng; Shufang Xu; Wei Yang; Wei Bao; Zhilei Shan; Xiaoqin Li; Liegang Liu
Journal:  Diabetologia       Date:  2020-02-07       Impact factor: 10.122

5.  A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.

Authors:  Gary Tong; Jun-Sheng Wang; Oleksandr Sverdlov; Shu-Pang Huang; Randy Slemmon; Robert Croop; Lorna Castaneda; Huidong Gu; Oi Wong; Hewei Li; Robert M Berman; Christina Smith; Charles F Albright; Randy Dockens
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

6.  Multiple inflammatory biomarker detection in a prospective cohort study: a cross-validation between well-established single-biomarker techniques and an electrochemiluminescense-based multi-array platform.

Authors:  Bas C T van Bussel; Isabel Ferreira; Marjo P H van de Waarenburg; Marleen M J van Greevenbroek; Carla J H van der Kallen; Ronald M A Henry; Edith J M Feskens; Coen D A Stehouwer; Casper G Schalkwijk
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

7.  Human plasma biomarker responses to inhalational general anaesthesia without surgery.

Authors:  Stacie Deiner; Mark G Baxter; Joshua S Mincer; Mary Sano; James Hall; Ismail Mohammed; Sid O'Bryant; Henrik Zetterberg; Kaj Blennow; Roderic Eckenhoff
Journal:  Br J Anaesth       Date:  2020-06-11       Impact factor: 9.166

Review 8.  Developing novel blood-based biomarkers for Alzheimer's disease.

Authors:  Heather M Snyder; Maria C Carrillo; Francine Grodstein; Kim Henriksen; Andreas Jeromin; Simon Lovestone; Michelle M Mielke; Sid O'Bryant; Manual Sarasa; Magnus Sjøgren; Holly Soares; Jessica Teeling; Eugenia Trushina; Malcolm Ward; Tim West; Lisa J Bain; Diana W Shineman; Michael Weiner; Howard M Fillit
Journal:  Alzheimers Dement       Date:  2014-01       Impact factor: 21.566

9.  Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker.

Authors:  Esther S Oh; Christopher M Marano; Jeannie-Marie Leoutsakos; Rebecca W Lee; Robert A Rissman; Gwenn S Smith; Suzanne Craft; Constantine G Lyketsos
Journal:  Alzheimers Dement (Amst)       Date:  2015-09

10.  Detection of amyloid-β42 using a waveguide-coupled bimetallic surface plasmon resonance sensor chip in the intensity measurement mode.

Authors:  Yeon Kyung Lee; Kyeong-Seok Lee; Won Mok Kim; Young-Soo Sohn
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.